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Poster Session II S269that preserves their anti-EBV specificity and functionality, can be la-
beled with 124I-MIBG and imaged by PET; 2) conditions for cell
preparation following pre-transfer thawing requires further optimi-
zation for improving PET imaging sensitivity.299
SAFETY OFMICAFUNGIN IN NEUTROPENIC PATIENTS INCLUDING THOSE
UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Wingard, J.R.1, Chandrasekar, P.2, Seibel, N.3, Sirohi, B.4, Ruhnke,M.5,
Powles, R.6 1University of Florida Shands Cancer Center, Gainesville, FL;
2Wayne State University School of Medicine, Karmanos Cancer Center,
Detroit, MI; 3National Institutes of Health, Bethesda, MD; 4Max Cancer
Centre, Max Healthcare, New Delhi, India; 5Campus Charite Mitte,
Humboldt University, Berlin, Germany; 6Parkside Oncology Clinic,
Wimbledon, London, United Kingdom
Polyenes and azoles have potentially deleterious drug interactions
that can lead to important renal and hepatic toxicities in HCT recip-
ients. The echinocandins may offer safety advantages in such pa-
tients. In this analysis using data from 8 clinical development
studies, we examined renal and hepatic parameters in 588 neutro-
penic patients who received micafungin for prophylaxis of fungal in-
fections (n5 375), treatment for invasive candidiasis/candidemia
(IC/C; n5 120), or treatment for invasive aspergillosis (IA,
n5 93). The renal and hepatic function laboratory parameters for
the 3 indications are shown in Table 1; changes in laboratory param-
eters were calculated for each indication and, for the prophylaxis pa-
tients, for type of HCT. The proportion of patients with an increase
in creatinine from\2*ULN at baseline to$2*ULN at EOT and an
increase in bilirubin and ALT\2.5*ULN at baseline to$2.5*ULN
were provided by indication. Overall, the changes in hepatic and re-
nal function laboratory parameters were consistent with the underly-
ing conditions of the patients, and HCT patients did not appear to
experience greater increases in levels of creatinine, bilirubin, and
ALT compared to patients in the other groups.Description of laboratory parameters in micafungin neutropenic pa
Parameter
All patients
(n5 588)
All prophylaxis
patients
(n5 375)
Proph
non
pat
(n5
Days of micafungin, median 17.5 18.0 6.0
Creatinine (mg/dl),
median (min-max)
Baseline 0.70 (0.1-6.6) 0.6 (0.1-5.4) 0.40 (
Peak 0.86 (0.3-2.2) 0.70 (0.1-4.4) 0.70 (
EOT 0.71 (0.1-6.9) 0.70 (0.1-4.4) 0.40 (
Increase from\2 ULN at
baseline to $2 ULN at EOT, n/N (%)
16/527 (3.0) 1/363 (0.3) —
Bilirubin (mg/dl),
median, (min-max)
Baseline 0.80 (0-17.2) 0.70 (0.0-7.3) 0.80 (
Peak 1.10 (0.2-23.5) 1.10 (0.4-23.5) 0.80 (
EOT 0.80 (0.1-37.9) 0.70 (0.1-31.3) 0.60 (
Increase from\2.5 ULN at
baseline to $2.5 ULN at
EOT, n/N (%)
39/490 (8.0) 17/355 (4.8) —
ALT (U/L), median, (min-max)
Baseline 27.0 (2-655) 26.5 (4-472) 30.0 (
Peak 30.0 (1-2151) 39.0 (7-389) 44.0 (
EOT 25.0 (1-2793) 24.0 (1-2793) 27.0 (
Increase from\2.5 ULN
at baseline to $2.5 ULN
at EOT, n/N (%)
35/455 (7.7) 17/315 (5.4) —
ALT5Alanine aminotransferase; EOT5end of treatment; IA5 invasive aspe
normal.
*Comprised of 89 non-HCT patients, 16 autologous HCT patients, and 5 alloge
not available for these subgroups.
†Comprised of 57 non-HCT patients, 5 autologous HCT patients, and 31 alloge
not available for these subgroups.300
SUCCESS WITH A SHORTER COURSE PREEMPTIVE TREATMENT FOR CY-
TOMEGALOVIRUS (CMV) REACTIVATION AFTER MYELOABLATIVE HLA
MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Naik, S.2, Shaenman, J.1, Kim, J.H.1, Wong, R.2, Arai, S.2,
Johnston, L.2, Brown, J.1,2 1Stanford University Medical Center, Stan-
ford, CA; 2Stanford University Medical Center, Stanford, CA
The optimal duration of preemptive treatment of CMV reactiva-
tion following HCT is unclear. We analyzed 355 evaluable patients
(pts) who underwent myeloablative HCT from an HLA matched
sibling donor at Stanford University Medical Center between 1996
and 2008. Either donor or recipient was seropositive for CMV at
the time of transplant for 287 (79%) pts. Median follow up time
was 3.8 years (0.3-10.4). Patients were screened weekly for reactiva-
tion in plasma using a qualitative (1996-2000) or quantitative PCR
CMV test (2001-2008) (Amplicor, Roche Molecular Diagnostics)
through day 100 post-HCT. CMV viremia was detected in 127
(44%) of the 287 pts. Any positive result prompted pre-emptive
treatment with ganciclovir at 5 mg/kg IV twice daily for two weeks
and a concurrent investigation for signs or symptoms suggestive of
CMV disease. For patients without evidence of CMV disease in
whom CMV viremia resolved during the first three weeks, ganciclo-
vir was administered at 5 mg/kg daily for an additional week. In pa-
tients with CMV disease or in whom viremia persisted, daily
ganciclovir was administered for an additional 4 weeks. There
were no substantial differences between groups with respect to sex,
age, race, or underlying disease. The relative paucity of CMV reac-
tivation in the D+/R– group is predicted by previously published ob-
servations. Pts who successfully resolved CMV viremia with the
administration of only 3 weeks of ganciclovir were less likely (1) to
have received a preparative regimen containing TBI, (2) more likely
to have a lower initial CMV load as compared with patients whomet
criteria for 6week treatment. However, no difference between the
groups was noted regarding GVHD or treatment with steroids at
the time of initial viremia. Our data supports the utility of a 3tients
ylaxis,
-HCT
ients
30)
Prophylaxis,
autologous
HCT patients
(n5 161)
Prophylaxis,
allogeneic
HCT patients
(n5 184)
IC/Candidemia
patients
(n5 120)*
IA patients
(n5 93)†
17.0 21.0 14.0 29.0
0.2-0.9) 0.70 (0.1-5.4) 0.60 (0.1-2.7) 0.98 (0.1-4.7) 0.90 (0.2-6.6)
0.7-0.7) 0.75 (0.5-0.8) 0.70 (0.2-2.3) 0.98 (0.1-4.7) 1.00 (0.2-3.8)
0.2-0.8) 0.70 (0.2-4.4) 0.70 (0.1-2.4) 0.91 (0.1-6.9) 1.00 (0.2-3.8)
— — 10/79 (12.7) 5/85 (5.9)
0.1-2.8) 0.60 (0-3.1) 0.70 (0.1-7.3) 1.20 (0.2-11.6) 1.10 (0.1-17.2)
0.1-2.8) 1.25 (0.5-4.4) 1.10 (0.4-23.5) 1.32 (0.1-9.3) 1.30 (0.1-37.9)
0.1-5.7) 0.60 (0.1-4.4) 0.90 (0.2-31.3) 1.17 (0.2-13.9) 1.30 (0.1-37.9)
— — 9/65 (13.8) 13/70(18.6)
13-129) 23.0 (4-370) 28.0 (4-472) 31.5 (7-204) 27.0 (2-655)
13-96) 26.0 (13-33) 46.0 (7-389) 57.0 (17-88) 34.0 (3-194)
8-167) 20.0 (4-383) 28.0 (1-2793) 30.0 (6-1119) 26.0 (3-313)
— — 8/68 (11.8) 10/72 (13.9)
rgillosis; IC/C5 invasive candidiasis/candidemia; ULN5 upper limits of
neic HCT patients. Renal and hepatic function laboratory parameter data
neic HCT patients. Renal and hepatic function laboratory parameter data
S270 Poster Session IIweek course of preemptive treatment with ganciclovir for pts at low
risk for CMV disease or prolonged reactivation.
Table 1. Demographics of all recipients of HCT from an HLA
matched sibling donor following a myeloablative preparative
regimen between 1996 and 2008
Pts withN5 (%)reactivation
onlyGCV
treatment*GCV
treatment*(no evidence
disease) 3wks 6wksTotal patients at risk 287(100) 83(29) 40(14) 43(13)
D1/R1 182(63) 55(30) 27(15) 28(15)
D1/R- 43(15) 3(7) 1(2) 2(5)
D-/R1 62(22) 25(40) 12(19) 13(21)
TBI 146(49) 39(47) 17(43) 22(51)
prophylactic steroids 122(42) 28(34) 17(43) 11(26)
**Treatment of GVHD ** 100(34) 26(31) 12(30) 14(33)
steroid 2 mg/kg 42(15) 10(12) 3(8) 7(16)
steroid 1 mg/kg 58(20) 16(19) 9(23) 7(16)
Median creatinine NA NA 1.1 1.3
median first PCR NA NA 940 1300
median maximum PCR NA NA 1300 4400*IV ganciclovir
** at time of first detected viremia.301
A PROSPECTIVE COMPARISON OF OUTCOMES AND RESOURCE UTILIZA-
TION IN PATIENTS WITH MYELOID MALIGNANCIES UNDERGOING ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) USING
MYELOABLATIVE OR REDUCED INTENSITY CONDITIONING
Gupta, V.1, Panzarella, T.2, Li, L.2, Khan, J.1, Alibhai, S.3, Galal, A.1,
Kuruvilla, J.1, Lipton, J.1, Messner, H.1 1Princess Margaret Hospital,
Toronto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Can-
ada; 3Toronto General Hospital, ON, Canada
We conducted a prospective study to compare outcomes, resource
utilization and quality of life (QOL) in patients with myeloid malig-
nancies undergoing alloHCT using myeloablatove (MY) or reduced
intensity conditioning (RIC). (QOL data submitted separately).
Patients with myeloid malignancies with a suitable matched re-
lated or unrelated donor, fit to undergo alloHCT using MY or
RIC were eligible for this study. The study was non-randomized
and primarily designed to determine whether RIC was as effective
as MY for the treatment of myeloid malignancies. The selection of
MY or RIC regimen was at the discretion of the treating physician.
The primary end point was leukemia-free survival (LFS) at 1-year.
Secondary end points were non-relapse mortality (NRM), relapse,
overall survival (OS), resource utilization and QOL. Patients were
enrolled from Jan 2005 to Sep 2008. Of the 118 eligible patients,
115 (MY 51; RIC 64) consented to participate. The outcomes and re-
source utilization data were collected at day30, day100, day180 and
day365.
Transplant indications included: AML, 83; MDS, 16; and other
myeloidmalignancies,16. 87 patients were of high and 28 of standard
risk. Apart from age, both study cohorts were well matched for base-
line patient, disease and transplant related characteristics. The me-
dian age of patients undergoing RIC was significantly higher than
those undergoing MY regimens (59 vs. 41 yrs, p\0.0001).
By univariate analysis, there were no differences in the RIC and
MY cohorts for 1-year LFS (53% vs. 58%, p5 0.60) and OS (61%
vs. 58%, p5 0.82). The outcomes were similar in multivariate anal-
ysis with LFS (HR 0.82, p5 0.61) and OS (HR 0.79, p5 0.55). No
significant differences were observed in the cumulative risk of NRM
or relapse at 1-year. Disease risk stratification was the only signifi-
cant factor for LFS (HR for standard risk 0.42, p5 0.02) and OS
(HR 0.34, p5 0.008).
Medical resources utilization was similar during the first 100 days.
From day 100 to day 365, the RIC cohort required a significantlyhigher number of in-patient hospital days (p\0.001), higher num-
ber of outpatient visits (p\0.0001) and a higher number of platelet
transfusions (p\0.0001).
We conclude that disease biology rather than intensity of the con-
ditioning therapy is major determinant of outcomes of alloHCT in
patients with myeloid malignancies. The utilization of medical re-
sources is higher after 100 days in the patients undergoing RIC.
Long-term follow up of this study is in progress.302
KIR HAPLOTYPE MAY INFLUENCE CLINICAL OUTCOME FOLLOWING
HLA-MATCHED SIBLING HAEMOPOIETIC STEM CELL TRANSPLANTATION
Heatley, S.L.1,3, Mullighan, C.G.2, Sullivan, L.C.3, Brooks, A.G.3,
Szer, J.4, Bradstock, K.5, Schwarer, A.P.6, Bardy, P.G.1,7 1Australian
Red Cross Blood Service, Adelaide, South Australia, Australia; 2St Jude
Children’s Research Hospital, Memphis, TN; 3University of Melbourne,
Melbourne, VC, Australia; 4Royal Melbourne Hospital, Melbourne, VC,
Australia; 5Westmead Hospital, Sydney, New South Wales, Australia;
6The Alfred Hospital, Melbourne, VC, Australia; 7Royal Adelaide Hospi-
tal, Adelaide, South Australia, Australia
Natural killer cell alloreactivity due to Killer cell Immunoglobu-
lin-like Receptors (KIR) repertoire has been reported to be advanta-
geous in haploidentical allogeneic haemopoietic stem cell
transplants (HSCT). Benefits include superior survival, reduced re-
lapse and graft versus host disease particularly in patients trans-
planted for Acute Myeloid Leukaemia (AML). However data from
HLA-matched sibling HSCT are inconsistent and recently other
models have been proposed to measure NK alloreactivity including
the missing ligand and KIR haplotype models.
We examined the association between KIR haplotype, relapse,
overall survival and acute graft versus host disease (aGvHD) in
a cohort of 147 HLA matched siblings undergoing HSCT. KIR
genotyping was by multiplex PCR-SSP and haplotypes were cate-
gorised as the A haplotype carrying the 2DL1, 2DL3, 3DL1,
2DS4 and framework genes, all other combinations were denoted
the B haplotype. Combinations of KIR haplotype were assigned to
each transplant according to the donor and then recipient haplo-
type ie AA-AA, AA-Bx, Bx-AA and Bx-Bx where Bx denotes either
BB or BA.
In the entire cohort relapse, overall survival and aGvHD were not
significantly associated with donor and recipient KIR haplotype.
However when only AML patients (n5 69) were considered AA do-
nors-Bx recipients had superior survival rates and those with AA-AA
the most inferior. Interestingly this was also true for grades II-IV
aGvHD, with AA-Bx having no aGvHD and AA-AA the most
(p5 0.032). Furthermore, when stratified to only include AML pa-
tients receiving myeloablative conditioning, an AA donor-AA recip-
ient had inferior overall survival (p5 0.015) and the most severe
aGvHD (p5 0.054).
KIR haplotype may influence the clinical outcome of HLA-
matched sibling HSCT, particularly in patients treated for Acute
Myeloid Leukaemia that had received myeloablative conditioning.303
UNMANIPULATED HLA-MISMATCHED/HAPLOIDENTICAL BLOOD AND
MARROW HEMATOPOIETIC STEM CELL TRANSPLANTATION
Huang, X. Peking University, Beijing, China
A novel approach to HLA mismatched/haploidentical blood and
marrow hematopoietic stem cell transplantation.
Peking University researchers developed a novel approach to
HLA-mismatched/haploidentical transplantation without in vitro
T cell depletion. More than 831 cases of haploidentical transplan-
tation have been fulfilled and the promising results have been
achieved.
Engraftment: Huang et al reported 171 patients underwent trans-
plantation with this protocol, all patients achieved hematopoietic re-
covery. There was no significant association between the extent of
HLA disparity and the time of myeloid or platelet recovry.
Multivariate analysis indicated that the number of CD34+ cells
(\2.19 106/kg) in allografts, and advanced disease stage were
